Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 5, 2005, Pages 2888-2897

  Cabassi, Aderville ^a,c   Coghi, Pietro ^a   Govoni, Paolo ^c   Barouhiel, Elisa ^a   Speroni, Ester ^d   Cavazzini, Stefania ^b   Cantoni, Anna Maria ^c   Scandroglio, Renato ^c   Fiaccadori, Enrico ^a  

^a Hypertension Unit   (Italy)

^b Toxicology Unit   (United Kingdom)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DOXAZOSIN; GLYCEROL; LOSARTAN; NORADRENALIN;

ADIPOCYTE; ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CACHEXIA; CATABOLISM; CONTROLLED STUDY; HEART FAILURE; LIPID METABOLISM; LIPOLYSIS; MALE; MICRODIALYSIS; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS FAT; VISCERA; WEIGHT REDUCTION;

ADIPOCYTES; ADIPOSE TISSUE; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CARBAZOLES; CHOLESTEROL ESTERASE; GLYCEROL; HEART RATE; LIPOLYSIS; LOSARTAN; MALE; NOREPINEPHRINE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHETIC NERVOUS SYSTEM; TRIGLYCERIDES; TYROSINE 3-MONOOXYGENASE;

EID: 18844447198     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1995     Document Type: Article

References (49)

1. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, Teixeira MM, Hellewell PG, Hooper J, Poole-Wilson PA, Coats AJ 1999 Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 20:683-693
2. Anker SD, Ponikowski F, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ 1997 Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349:1050-1053
3. The CONSENSUS Trial Study Group 1987 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435
4. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI 1997 Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752
5. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL Carvedilol Prospective Randomized Cumulative Survival Study Group 2001 Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658
6. Zimmerman BG, Sybertz EJ, Wong PC 1984 Interaction between sympathetic and renin-angiotensin system. J Hypertens 2:581-587
7. Saxena PR 1992 Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 19(Suppl 6):S80-S88
8. Engeli S, Negrel R, Sharma AM 2000 Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35:1270-1274
9. Jones BH, Standridge MK, Moustaid N 1997 Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 138:1512-1519
10. Cassis LA, Dwoskin LP 1991 Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. J Neural Transm 34:129-137
11. English V, Cassis L 1999 Facilitation of sympathetic neurotransmission contributes to angiotensin regulation of body weight. J Neural Transm 106:631-644
12. Boschmann M, Ringel J, Klaus S, Sharma AM 2001 Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 9:486-491
13. Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, Stoffels M, Sharma AM, Luft FC, Klaus S 2003 Tissue-specific response to interstitial angiotensin II in humans. Hypertension 41:37-41
14. Goossens GH, Blaak EE, Saris WH, van Baak MA 2004 Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 89:2690-2696
15. Gronan RJ, York DH 1979 Effects of chronic intraventricular administration of angiotensin II on drinking behavior and blood pressure. Pharmacol Biochem Behav 10:121-126
16. Kabour A, Henegar JR, Devineni VR, Janicki JS 1995 Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 29:543-548
17. Brink M, Wellen J, Delafontaine P 1996 Angiotensin II causes weight loss and decreases circulating insulin-like growth factor 1 in rats through a pressor-independent mechanism. J Clin Invest 97:2509-2516
18. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA 1998 Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 274:E867-E876
19. Cassis L, Helton M, English V, Burke G 2002 Angiotensin II regulates oxygen consumption. Am J Physiol 282:R445-R453
20. Porter JP, Potratz KR 2004 Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol 287:R422-R428
21. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P 2001 Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor 1. Endocrinology 142:1489-1496
22. Bamshad M, Aoki VT, Adkison MG, Warren WS, Bartness TJ 1998 Central nervous system origins of the sympathetic nervous system outflow to white adipose tissue. Am J Physiol 275:R291-R299
23. Rebuffe-Scrive M 1991 Neuroregulation of adipose tissue: molecular and hormonal mechanisms. Int J Obes 15(Suppl 2):83-86
24. Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Bohm M 2000 Binding properties of β-blockers at recombinant β1-, β2-, and β3-adrenoceptors. J Cardiovasc Pharmacol 36:466-471
25. Cabassi A, Vinci S, Calzolari M, Bruschi G, Borghetti A 1998 Regional sympathetic activity in pre-hypertensive phase of spontaneously hypertensive rats. Life Sci 62:1111-1118
26. Cabassi A, Bergamaschi E, Mutti A, Franchini I, Borghetti A 1996 Age-related changes in interstitial norepinephrine. A microdialysis study in spontaneously hypertensive rats. Am J Hypertens 9:878-883
27. Cabassi A, Vinci S, Cantoni AM, Quartieri F, Moschini L, Cavazzini S, Cavatorta A, Borghetti A 2002 Sympathetic activation in adipose tissue and skeletal muscle of hypertensive rats. Hypertension. 39:656-661
28. Hickner RC, Rosdahl H, Borg I, Ungerstedt U, Jorfeldt L, Henriksson J 1991 Ethanol may be used with the microdialysis technique to monitor blood flow changes in skeletal muscle: dialysate glucose concentration is blood-flow-dependent. Acta Physiol Scand 143:355-366
29. Holm C, Osterlund T, Laurell H, Contreras JA 2000 Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Annu Rev Nutr 20:365-393
30. Bernst E, Gutmann I 1974 Determination with alcohol dehydrogenase and NAD. In: Bergmeyer HU, ed. Methods of enzymatic analysis. Weinheim, Germany: Verlag Chemie; 1499-1505
31. Langfort J, Ploug T, Ihlemann J, Saldo M, Holm C, Galbo H 1999 Expression of hormone-sensitive lipase and its regulation by adrenaline in skeletal muscle. Biochem J 340:459-465
32. Pedersen EB, Danielsen H, Jensen T, Madsen M, Sorensen SS, Thomsen OO 1986 Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. Eur J Clin Invest 16:56-60
33. Yang CC, Chan JY, Chan SH 1993 Unsustained dipsogenic response to chronic central infusion of angiotensin-III in spontaneously hypertensive rats. Endocrinology 132:405-409
34. Li JB, Wassner SJ 1986 Protein synthesis and degradation in skeletal muscle of chronically uremic rats. Kidney Int 29:1136-1143
35. Cassis LA, English VL, Bharadwaj K, Boustany CM 2004 Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 145:169-174
36. Kraemer FB, Shen WJ 2002 Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. J Lipid Res 43:1585-1594
37. Cherradi N, Pardo B, Greenberg AS, Kraemer FB, Capponi AM 2003 Angiotensin II activates cholesterol ester hydrolase in bovine adrenal glomerulosa cells through phosphorylation mediated by p42/p44 mitogen-activated protein kinase. Endocrinology 144:4905-4915
38. Galitzky J, Lafontan M, Nordenstrom J, Arner P 1993 Role of vascular α-2 adrenoceptors in regulating lipid mobilization from human adipose tissue. J Clin Invest 91:1997-2003
39. Lafontan M, Berlan M 1995 Fat cell α2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr Rev 16:716-738
40. Tavernier G, Barbe P, Galitzky J, Berlan M, Caput D, Lafontan M, Langin D 1996 Expression of β3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. J Lipid Res 37:87-97
41. Louis SN, Jackman GP, Nero TL, Iakovidis D, Louis WJ 2000 Role of β-adrenergic receptor subtypes in lipolysis. Cardiovasc Drugs Ther 14:565-577
42. Geloen A, Collet AJ, Bukowiecki LJ 1992 Role of sympathetic innervation in brown adipocyte proliferation. Am J Physiol 263:R1176-R1181
43. Frayn KN, Karpe F, Fielding BA, MacDonald IA, Coppack SW 2003 Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 27:875-888
44. Coats AJ, Anker SD, Roecker EB, Schultz MK, Staiger C, Amann-Zalan I, Shusterman N, Packer M, Prevention and reversal of cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS Study. Prog of the American Heart Association Scientific Sessions, Anaheim, CA, 2001 (Abstract 2071)
45. Anker SD, Lechat P, Dargie HJ 2003 Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS-II study. J Am Coll Cardiol 41(Suppl 1):156-157 (Abstract)
46. Hryniewicz K, Androne AS, Hudaihed A, Katz SD 2003 Partial reversal of cachexia by β-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 9:464-468
47. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC 2001 Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250-254
48. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S 2003 Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet 361:1077-1083
49. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH 2000 Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol 278:E941-E948